| __timestamp | HUTCHMED (China) Limited | Madrigal Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 26684000 | 15746000 |
| Thursday, January 1, 2015 | 29829000 | 13392000 |
| Friday, January 1, 2016 | 39578000 | 9290000 |
| Sunday, January 1, 2017 | 43277000 | 7672000 |
| Monday, January 1, 2018 | 48645000 | 15293000 |
| Tuesday, January 1, 2019 | 52934000 | 22648000 |
| Wednesday, January 1, 2020 | 61349000 | 21864000 |
| Friday, January 1, 2021 | 127125000 | 37318000 |
| Saturday, January 1, 2022 | 136106000 | 48130000 |
| Sunday, January 1, 2023 | 133175999 | 108146000 |
Igniting the spark of knowledge
In the dynamic world of biopharmaceuticals, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Madrigal Pharmaceuticals, Inc. and HUTCHMED (China) Limited from 2014 to 2023. Over this period, HUTCHMED's SG&A expenses surged by approximately 400%, peaking in 2022. Meanwhile, Madrigal Pharmaceuticals saw a staggering increase of over 580%, with a notable spike in 2023.
These trends highlight the companies' differing strategies in navigating the competitive biopharma landscape, with HUTCHMED focusing on consistent growth and Madrigal making bold, strategic leaps.
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and HUTCHMED (China) Limited
Breaking Down SG&A Expenses: argenx SE vs Madrigal Pharmaceuticals, Inc.
Summit Therapeutics Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Madrigal Pharmaceuticals, Inc.
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Opthea Limited Trends and Insights
Selling, General, and Administrative Costs: Madrigal Pharmaceuticals, Inc. vs Verona Pharma plc
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Viking Therapeutics, Inc.
Madrigal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
Madrigal Pharmaceuticals, Inc. or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: MorphoSys AG vs HUTCHMED (China) Limited
Operational Costs Compared: SG&A Analysis of Catalyst Pharmaceuticals, Inc. and HUTCHMED (China) Limited
Cost Management Insights: SG&A Expenses for HUTCHMED (China) Limited and Soleno Therapeutics, Inc.